Allergan’s Nasal Spray For Frequent Nighttime Urination Gets Cautious Panel Nod

Desmopressin's limited efficacy over placebo doesn't dissuade FDA's advisory committee, which votes 14 to 4 in favor of approval even as many suggest indication be narrowed.

An FDA advisory panel concluded that the limited benefits of Serenity Pharmaceuticals LLC/Allergan PLC’s desmopressin nasal spray for nocturia – essentially cutting down nighttime trips to the bathroom by a few times per week – outweigh its risks and recommended approval.

However, many members advised FDA to limit the indication to treatment of nocturnal polyuria, which is present in about 80%...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers